Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
0 competitors in Congenital Heart Disease
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Qaialdo
In the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. Neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5.1 and 5.2).
View on EMAIron-deficiency
Obesity
Pediatric Pulmonary Hypertension
Covid19
Microalbuminuria
